Inventurus Knowledge Solutions Ltd (IKS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Inventurus Knowledge Solutions Ltd on NSE and BSE, with an AI summary of each filing.
Enclosed is the intimation of Earnings Conference Call on Q2 FY 2026-27 Results scheduled to be held on Friday, November 6, 2026.
Intimation · 06 Nov 2026, 8:30 am
Inventurus Knowledge Solutions Schedules Q2 FY27 Earnings Call on 6th Nov'26 Inventurus Knowledge Solutions Limited (NSE: IKS, BSE: 544309) will host its Q2 FY27 earnings conference call on Friday, 6th Nov'26, at 8:30 AM IST. Dial-in access is available via universal numbers (+91 22 6280 1144 / +91 22 7115 8045) alongside international toll-free numbers across key regions including the USA, UK, Singapore, and Hong Kong. Investor queries can be directed to Investor Relations at investor_relations@ikshealth.com.
Inventurus Knowledge Solutions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the unaudited ....
Intimation · 05 Nov 2026, 5:30 am
Inventurus Knowledge Solutions Schedules Board Meeting for Q2 FY27 Financial Results Inventurus Knowledge Solutions Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, pursuant to SEBI insider trading regulations, the trading window for dealing in the company’s securities by designated persons and their immediate relatives remains closed from 1st Oct'26 until 7th Nov'26 (both days inclusive).
Inventurus Knowledge Solutions Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026.
Intimation · 05 Nov 2026, 5:30 am
Enclosed is the Investor/Analyst Meet intimation to be held on September 30, 2026.
Intimation · 25 Sept 2026, 10:01 pm
Inventurus Knowledge Solutions Schedules Institutional Investor Meet in Pune Inventurus Knowledge Solutions Limited has scheduled an analyst and institutional investor meeting on 30th Sep'26 at 10:00 AM IST in Pune. The company will interact with representatives from Bajaj Mutual Fund, Bajaj General, and Oaklane Capital. Management confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the interaction.
Enclosed is the Analyst/ Institutional Investor Meet intimation.
Intimation · 24 Sept 2026, 1:27 am
Inventurus Knowledge Solutions Schedules Institutional Investor Meet in Chennai Inventurus Knowledge Solutions Limited has scheduled an analyst and institutional investor meeting on 28th Sep'26 at 10:00 AM IST in Chennai. The company is set to meet with institutional funds including Franklin Templeton, Sundaram Mutual Fund, Unifi Capital, and Unifi Mutual Fund. No unpublished price-sensitive information (UPSI) will be shared during the interaction.
Enclosed is the Voting Results along with Scrutinizer''s Report of the 20th Annual General Meeting held on September 21, 2026.
Annual General Meeting · 23 Sept 2026, 1:24 am
Proceedings of 20th Annual General Meeting of the Company is enclosed.
Annual General Meeting · 22 Sept 2026, 1:33 am
Enclosed is the schedule of investor meet.
Intimation · 16 Sept 2026, 3:24 am
Inventurus Knowledge Solutions Schedules Institutional Investor Meet Inventurus Knowledge Solutions Limited (NSE: IKS, BSE: 544309) will participate in the 2026 Jefferies India Forum on Thu, 17th Sep'26, from 10:00 AM to 06:00 PM IST. The multi-investor meeting will take place at The Pavilion at Trident, Gurgaon. The company finalized the meeting at short notice and confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the interactions.
Enclosed is the disclosure regarding change in Senior Management Personnel of the Company.
Change in Management · 04 Sept 2026, 5:55 pm
Letter sent to members pursuant to Regulation 36(1)(b) of SEBI Listing Regulations is enclosed.
Others (Uncategorized) · 28 Aug 2026, 10:41 pm
IKS Health Announces 20th AGM and FY26 Annual Report Inventurus Knowledge Solutions (IKS Health) will hold its 20th Annual General Meeting (AGM) on 21 Sep'26 at 5:30 PM IST via video conference. The company has released its Annual Report for FY 2025-26. The cut-off date for shareholder eligibility for remote e-voting is 14 Sep'26. The remote e-voting period will be open from 09:00 AM on 17 Sep'26 until 05:00 PM on 20 Sep'26. This notice complies with Regulation 30 of SEBI LODR regulations.
Business Responsibility and Sustainability Report for FY 2025-26 is enclosed.
Others (Uncategorized) · 28 Aug 2026, 8:52 pm
IKS Health FY26 Business Responsibility & Sustainability Report IKS Health's FY26 exports contributed approx. 100% of total turnover, primarily from US clients. Total employees reached 9,760 as of 31-Mar'26. Permanent employee turnover for FY26 was 37.41%, down from 50.77% in FY25. Related party sales rose to 49.02% of total sales, up from 20.04% in FY25. Total energy consumption increased to 16,808 GJ from 14,741 GJ YoY, while energy intensity per rupee of turnover improved to 1.13 from 1.51. A penalty of ₹1.74M was paid for FY26 regarding past SEIS benefit claims.
Notice of 20th AGM of the Company to be held on Monday, September 21, 2026 at 5.30 pm IST is enclosed.
Annual General Meeting · 28 Aug 2026, 8:48 pm
Notice convening the 20th Annual General Meeting ('AGM') and Annual Report 2025-26. We hereby inform you that the 20th AGM of the Company will be held on Monday, September 21, 2026 at ....
Others (Uncategorized) · 28 Aug 2026, 8:43 pm
Ref: Our intimation dated August 11, 2026 for Schedule of Analyst/ Institutional Investor Meet. Sub: Change in Schedule of Analyst/ Institutional Investor Meet. In continuation of ....
Intimation · 14 Aug 2026, 12:10 am
IKS Health Reschedules Analyst Meet at Motilal Oswal Conference IKS Health has rescheduled its Analyst/Institutional Investor meet, originally planned for 18 Aug'26. The meeting will now take place on 19 Aug'26, from 10:00 AM to 06:00 PM IST, at the Motilal Oswal 22nd Annual Global Investor Conference held at Grand Hyatt, Mumbai. The company confirmed it will engage with multiple investors and stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed. The schedule remains subject to change.
Ref: Our intimation dated August 11, 2026 for Schedule of Analyst/ Institutional Investor Meet. Sub: Schedule of Analyst/ Institutional Investor Meet - Update. In continuation to ....
Intimation · 14 Aug 2026, 12:07 am
IKS Health Announces Temasek Participation in Aug'26 Investor Meet IKS Health will host a physical, one-on-one analyst/investor meet on 14 Aug'26 in BKC, Mumbai. The company has updated the schedule, adding Temasek to the list of participants. Other key investors attending include Aditya Birla Sun Life AMC, ICICI Prudential AMC, SBI MF, HDFC AMC, 3P Investment Managers, and Value Quest. The company stated no unpublished price-sensitive information will be shared. The schedule is subject to change.
Transcript of the Q1 FY 2026-27 Earnings Conference Call. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed ....
Transcript · 12 Aug 2026, 4:29 am
IKS Health Q1 FY27: Strong Growth, TruBridge Integration Outlook IKS Health reported strong Q1 FY27 results with revenue of INR 893cr, up 21% YoY (12% in constant currency), and EBITDA of INR 294cr at a 33% margin. Adjusted for INR 20cr in one-time TruBridge acquisition costs, EBITDA was INR 314cr (35% margin). Management reaffirmed its FY30 "True North" EBITDA target of INR 3,000cr, which it aims to achieve without further dilution. The combined IKS/TruBridge business starts with ~$688M annualized revenue, with IKS aspiring for 12%+ organic growth.
In terms of Regulation 30(6) read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you ....
Intimation · 11 Aug 2026, 10:53 pm
IKS Health Announces Participation in Motilal Oswal Investor Conference IKS Health (NSE: IKS) will meet with multiple institutional investors on 18th Aug'26 at the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the event. This interaction provides a platform for management to engage with the investment community. The scheduled meeting is subject to potential changes.
In terms of Regulation 30(6) read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you ....
Intimation · 11 Aug 2026, 10:50 pm
IKS Health Announces Institutional Investor Meetings on 14 Aug'26 IKS Health will conduct a series of one-on-one, physical meetings with institutional investors on 14 Aug'26 in BKC, Mumbai. The event is scheduled from 11:00 a.m. to 05:00 p.m. IST. Participating investors include Aditya Birla Sun Life AMC, ICICI Prudential AMC, SBI MF, HDFC AMC, 3P Investment Managers, and Value Quest. The company has confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these meetings. The schedule is subject to potential changes.
Audio recording of the Earnings Conference Call held on Thursday, August 06, 2026. This is in continuation of our earlier letter dated July 31, 2026 and pursuant to Regulation 30 and ....
Audio / Video · 06 Aug 2026, 8:57 pm
IKS Health Publishes Q1 FY27 Earnings Call Audio Recording IKS Health has made the audio recording of its Q1 FY26-27 earnings conference call available on its corporate website. The call, which discussed the company's quarterly results, was held on Thu, 06 Aug'26. This disclosure complies with SEBI's Listing Obligations and Disclosure Requirements regulations. The recording provides investors and analysts with direct access to management's discussion and outlook following the earnings release. The company's BSE Scrip Code is 544309 and NSE Symbol is IKS.
Enclosed is disclosure with respect to agreement entered into.
Others (Uncategorized) · 06 Aug 2026, 2:54 pm
IKS Health Subsidiary to Sell Abridge AI Stake for USD 10M Inventurus Knowledge Solutions' wholly-owned subsidiary, IKS Inc., has entered into a Stock Purchase Agreement on 05 Aug'26 to divest its stake in Abridge AI Inc. IKS Inc. will sell 54,055 Series A-1 Preferred Shares to Alpha Square Group Fund IV, LP for an aggregate consideration of USD 10,000,175. The transaction represents a monetization/partial divestment of its holdings. The deal is not a related-party transaction and does not involve parties related to the promoter group.
Enclosed is disclosure with respect to change in directors of the company.
Change in Management · 06 Aug 2026, 4:31 am
IKS Health Announces Board Leadership Transition On 5th Aug'26, Inventurus Knowledge Solutions' board announced Chairman Berjis Desai will retire upon conclusion of the 20th AGM. Mr. Desai declined reappointment following his appointment as a Member of the National Commission for Minorities. The board has designated current Independent Director, Mr. Clarence Carleton King II, to succeed him as the new Non-Executive Chairman and Independent Director. Both changes will be effective upon the conclusion of the upcoming AGM. The cessation date for Mr. Desai is noted as 21st Sep'26.
Enclosed.
Financial Result · 06 Aug 2026, 4:20 am
Inventurus Knowledge Solutions Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 8,936 (+20.7% YoY | +4.2% QoQ) ■ EBIT: 2,607 (+24.2% YoY | -2.1% QoQ) ■ EBIT Margin (%): 29.2 (+81 bps YoY | -187 bps QoQ) ■ PAT: 1,937 (+27.8% YoY | -5.9% QoQ) ■ EPS (INR): 11.3 (+27.9% YoY | -6.1% QoQ)
Enclosed is the investor presentation.
Investor Presentation · 06 Aug 2026, 3:51 am
IKS Health Q1 FY27: Strong Revenue Growth and Margin Expansion IKS Health reported strong Q1 FY27 results with revenue of INR 8,936 mn, up 20.7% YoY, and profit after tax (PAT) of INR 1,937 mn, a 27.8% YoY increase. EBITDA grew 24.0% YoY to INR 2,949 mn, yielding a 33.0% margin despite one-time acquisition costs. Adjusted PAT rose 28.0% YoY to INR 2,153 mn. Strong cash generation continued with Free Cash Flow (FCF) growing 26.9% YoY to INR 1,742 mn. Net debt stood at INR 2,654 mn as of 30 Jun'26.
Enclosed is the press release.
Press Release · 06 Aug 2026, 3:46 am
IKS Health Reports Strong Q1 FY27 with 21% Revenue and 28% PAT Growth IKS Health reported strong Q1 FY27 results ending 30 Jun'26, with revenue growing 20.7% YoY to INR 8,936 Mn. EBITDA increased 24% YoY to INR 2,949 Mn, with a margin of 33%. Profit After Tax (PAT) rose 27.8% YoY to INR 1,937 Mn, yielding a PAT margin of 21.7%. Adjusted PAT grew 28% YoY to INR 2,153 Mn, representing a 24.1% margin. The company cited cost discipline, platform scalability, and capital efficiency as key drivers for the robust performance and margin protection.